Daily Treatment & Standard of Care
At a Glance
The key treatment for NAGS deficiency is daily carglumic acid, which helps the body remove waste nitrogen and control ammonia. Doses should not be interrupted, and the metabolic team must guide protein changes and plans for vomiting, missed doses, emergencies, and medication access.
While the diagnosis of NAGS deficiency is a serious lifelong commitment, the standard of care is built around a highly effective medication that can transform the trajectory of the condition. For most patients, daily life revolves around maintaining a steady level of this medication in the body to keep the urea cycle “engine” running smoothly [1][2].
The Role of Carglumic Acid
The cornerstone treatment for NAGS deficiency is carglumic acid (brand name Carbaglu). This medication is an analogue (a look-alike) of the missing N-acetylglutamate (NAG) [3].
Because it mimics the natural “key” that starts the urea cycle, it directly activates the CPS1 enzyme [3]. When taken regularly, carglumic acid allows the body to process waste nitrogen into urea just as it would if the NAGS enzyme were present [1]. In many cases, this treatment is so precise that it can normalize blood ammonia and citrulline levels [4].
Medication Safety: Administration and Vomiting
Carglumic acid is a life-supporting treatment, so handling it properly is crucial:
- Preparation: The medication typically comes in dispersible tablets that must be dissolved in a small amount of water before taking. Follow your pharmacist’s specific preparation instructions.
- Missed Doses: You must have a written plan from your doctor about what to do if a dose is missed. Never double a dose on your own without consulting your metabolic team.
- Vomiting: If you or your child vomits immediately after a dose, or if repeated vomiting prevents the medication from staying down, you are at risk for a rapid ammonia spike. Contact your metabolic team immediately or proceed to the emergency department, as IV support may be needed [4].
Diet and Protein Liberalization
One of the most significant benefits of carglumic acid for NAGS deficiency is its impact on diet. In many other urea cycle disorders, patients must follow extremely strict, low-protein diets for their entire lives [5].
In NAGS deficiency, successful treatment may allow for protein liberalization—meaning you or your child may be able to eat a more normal amount of protein [4]. Some clinical reports show that once the medication dose is stable, doctors may relax protein restrictions [4]. However, you must never change or liberalize protein intake without the guidance of your metabolic dietitian. They will set specific daily protein targets based on your lab results, growth, and how your body responds to the medication [4][6].
The Critical Importance of Consistency
The most vital rule of living with NAGS deficiency is that carglumic acid access must never be interrupted [4]. Disrupting carglumic acid can lead to a rapid and dangerous rise in ammonia [4].
- Rapid Risk: Without the medication, the body can quickly enter a hyperammonemic crisis [4].
- Documented Dangers: Medical records have shown that interruptions—caused by things like insurance delays or difficulty administering the drug during illness—can lead to poor long-term neurological outcomes [4].
- Emergency Preparedness: You should always have an emergency supply of medication and a clear plan for what to do if you cannot access it (such as during travel or prior authorization renewals) [4].
By treating carglumic acid as an essential life-support system and working closely with your dietitian, most people with NAGS deficiency can maintain excellent metabolic control [7][1].
Common questions in this guide
What is the standard treatment for NAGS deficiency?
What happens to protein intake after carglumic acid starts working?
What should I do if a dose of carglumic acid is missed?
What should I do if vomiting happens after a dose?
Why is it dangerous to stop carglumic acid?
How can we prevent a gap in carglumic acid treatment?
How often should ammonia and citrulline levels be checked?
Get notified when new evidence is published on Hyperammonemia due to N-acetylglutamate synthase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
Partial N-acetyl glutamate synthase deficiency presenting as postpartum hyperammonemia: Diagnosis and subsequent pregnancy management.
Abou Haidar L, Pachnis P, Gotway GK, et al.
JIMD reports 2023; (64(6)):403-409 doi:10.1002/jmd2.12388.
PMID: 37927481 - 2
Efficacy of N-carbamoyl-L-glutamic acid for the treatment of inherited metabolic disorders.
Chapel-Crespo CC, Diaz GA, Oishi K
Expert review of endocrinology & metabolism 2016; (11(6)):467-473 doi:10.1080/17446651.2016.1239526.
PMID: 30034506 - 3
N-Acetylglutamate Synthase Deficiency Due to a Recurrent Sequence Variant in the N-acetylglutamate Synthase Enhancer Region.
Williams M, Burlina A, Rubert L, et al.
Scientific reports 2018; (8(1)):15436 doi:10.1038/s41598-018-33457-0.
PMID: 30337552 - 4
The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency.
Singh RH, Bourdages MH, Kurtz A, et al.
Orphanet journal of rare diseases 2024; (19(1)):168 doi:10.1186/s13023-024-03167-0.
PMID: 38637895 - 5
Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy.
Das AM
Metabolic brain disease 2025; (40(5)):192 doi:10.1007/s11011-025-01619-5.
PMID: 40285952 - 6
Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.
Kenneson A, Singh RH
Orphanet journal of rare diseases 2020; (15(1)):279 doi:10.1186/s13023-020-01560-z.
PMID: 33036647 - 7
Early care of N-acetyl glutamate synthase (NAGS) deficiency in three infants from an inbred family.
Peoc'h K, Damaj L, Pelletier R, et al.
Molecular genetics and metabolism reports 2020; (22()):100558 doi:10.1016/j.ymgmr.2019.100558.
PMID: 32021803
This page is for informational purposes only and does not constitute medical advice. Your metabolic team and dietitian should guide carglumic acid dosing, protein intake, and emergency steps.